Lexicon Pharmaceuticals (LXRX)
(Real Time Quote from BATS)
$1.84 USD
+0.07 (3.96%)
Updated May 9, 2024 11:10 AM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Lexicon Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -177.12 | -101.94 | -87.76 | -58.57 | 130.13 |
Depreciation/Amortization & Depletion | 2.33 | 1.17 | 0.35 | 3.95 | 33.76 |
Net Change from Assets/Liabilities | 2.66 | 0.40 | -10.23 | 31.08 | -58.29 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 10.24 | 11.52 | 10.63 | -119.42 | 8.20 |
Net Cash From Operating Activities | -161.90 | -88.85 | -87.02 | -142.97 | 113.81 |
Property & Equipment | -0.47 | -1.33 | -1.22 | 10.93 | -0.07 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -49.47 | -69.75 | 3.33 | 369.83 | -155.79 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -49.94 | -71.08 | 2.11 | 380.76 | -155.86 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 138.00 | 93.34 | 34.41 | 68.94 | -0.94 |
Issuance (Repayment) of Debt | 49.96 | 48.87 | -11.70 | -216.58 | -1.29 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 187.96 | 142.21 | 22.71 | -147.64 | -2.23 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -23.88 | -17.72 | -62.20 | 90.15 | -44.27 |
Cash at Beginning of Period | 46.35 | 64.07 | 126.26 | 36.11 | 80.39 |
Cash at End of Period | 22.47 | 46.35 | 64.07 | 126.26 | 36.11 |
Diluted Net EPS | -0.80 | -0.62 | -0.60 | -0.53 | 1.16 |
Fiscal Year End for Lexicon Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -48.40 | -177.12 | -127.36 | -76.84 | -31.93 |
Depreciation/Amortization & Depletion | 0.66 | 2.33 | 1.56 | 0.79 | 0.38 |
Net Change from Assets/Liabilities | -11.47 | 2.66 | 6.94 | -0.92 | -3.47 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 4.08 | 10.24 | 7.52 | 7.23 | 3.42 |
Net Cash From Operating Activities | -55.13 | -161.90 | -111.35 | -69.73 | -31.61 |
Property & Equipment | 0.00 | -0.47 | -0.47 | -0.39 | -0.25 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -110.22 | -49.47 | -101.37 | -62.13 | 12.34 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -110.22 | -49.94 | -101.84 | -62.52 | 12.09 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 239.78 | 138.00 | 138.00 | 138.21 | -0.82 |
Issuance (Repayment) of Debt | 0.00 | 49.96 | 49.96 | 49.96 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.40 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 239.38 | 187.96 | 187.96 | 188.17 | -0.82 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 74.03 | -23.88 | -25.23 | 55.93 | -20.34 |
Cash at Beginning of Period | 22.47 | 46.35 | 46.35 | 46.35 | 46.35 |
Cash at End of Period | 96.49 | 22.47 | 21.12 | 102.27 | 26.00 |
Diluted Net EPS | -0.20 | -0.20 | -0.21 | -0.22 | -0.17 |